|
| | Publication Year | Title | Author(s) |
| 61 | 2019 | The Impact of Universal Immunohistochemistry on Lynch Syndrome Diagnosis in an Australian Colorectal Cancer Cohort. | Loh, Zoe ; Williams, David S ; Salmon, Lucinda ; Dow, Eryn; John, Thomas |
| 62 | 2019 | Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials. | Tiu, Crescens; Loh, Zoe ; Gan, Chun Loo; Gan, Hui K ; John, Thomas ; Hawkes, Eliza A |
| 3 | Dec-2018 | EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. | John, Thomas ; Akamatsu, Hiroaki; Delmonte, Angelo; Su, Wu-Chou; Lee, Jong Seok; Chang, Gee-Chen; Huang, Xiangning; Jenkins, Suzanne; Wu, Yi-Long |
| 4 | Sep-2018 | LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC. | Lee, Rachael Chang; Thapa, Bibhusal ; John, Thomas |
| 5 | Jun-2018 | Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC? | Klevansky, Myron ; John, Thomas |
| 6 | 1-Apr-2018 | Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort? | John, Thomas ; Chia, Puey Ling |
| 7 | Feb-2018 | In Reply to Leone. | Do, Hongdo; Arulananda, Surein; John, Thomas ; Dobrovic, Alexander |
| 8 | 19-Jan-2018 | Personalized chemosensitivity assays for mesothelioma- is it worth the effort? | John, Thomas ; Chia, Puey Ling |
| 9 | 2018 | Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. | Arulananda, Surein; Thapa, Bibhusal ; Walkiewicz, Marzena; Zapparoli, Giada V; Williams, David S ; Dobrovic, Alexander ; John, Thomas |
| 10 | 2018 | Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer | Ramalingam, Suresh S; Yang, James C-H; Lee, Chee Khoon; John, Thomas ; Kurata, Takayasu; Nogami, Naoyuki; Ohe, Yuichiro; Kim, Dong-Wan; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Barrett, J Carl; Thress, Kenneth S; Jänne, Pasi A |
| 11 | 2018 | Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. | Metaxas, Yannis; Rivalland, Gareth; Klingbiel, Dirk; Kao, Steven; Schmid, Sabine; Nowak, Anna K; Gautschi, Oliver; Bartnick, Tammo; Hughes, Brett G; Bouchaab, Hasna; Rothschild, Sacha; Pavlakis, Nick; Wolleb, Sybille; Petrausch, Ulf; O'Byrne, Kenneth; Froesch, Patrizia; Löffler-Baumann, Melanie; Pratsch-Peter, Susanne; Russell, Prudence; Mingrone, Walter; Savic, Spasenija; Thapa, Bibhusal ; Früh, Martin; Pless, Miklos; von Moos, Roger; Mauti, Laetitia; John, Thomas |
| 12 | 1-Nov-2017 | Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial | Grosso, Federica; Steele, Nicola; Novello, Silvia; Nowak, Anna K; Popat, Sanjay; Greillier, Laurent; John, Thomas ; Leighl, Natasha B; Reck, Martin; Taylor, Paul; Planchard, David; Sørensen, Jens Benn; Socinski, Mark A; von Wangenheim, Ute; Loemb´e, Ars`ene Bienvenu; Barrueco, Jos´e; Morsli, Nassim; Scagliotti, Giorgio |
| 13 | Nov-2017 | Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. | Arulananda, Surein; Do, Hongdo; Musafer, Ashan; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas |
| 14 | Nov-2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Ahn, Myung-Ju; Kim, Dong-Wan; Chul Cho, Byoung; Kim, Sang-We; Lee, Jong Seok; Ahn, Jin-Seok; Kim, Tae Min; Lin, Chia-Chi; Kim, Hye Ryun; John, Thomas ; Kao, Steven; Goldman, Jonathan W; Su, Wu-hou; Natale, Ronald; Rabbie, Sarit; Harrop, Bryony; Overend, Philip; Yang, Zhenfan; Yang, James Chih-Hsin |
| 15 | Nov-2017 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. | Hendry, Shona; Salgado, Roberto; Gevaert, Thomas; Russell, Prudence A; Thapa, Bibhusal ; Christie, Michael; van de Vijver, Koen; Estrada, M V; Gonzalez-Ericsson, Paula I; Sanders, Melinda; Solomon, Benjamin; Solinas, Cinzia; Van den Eynden, Gert G G M; Allory, Yves; Preusser, Matthias; Hainfellner, Johannes; Pruneri, Giancarlo; Vingiani, Andrea; Demaria, Sandra; Symmans, Fraser; Nuciforo, Paolo; Comerma, Laura; Thompson, E A; Lakhani, Sunil; Kim, Seong-Rim; Schnitt, Stuart; Colpaert, Cecile; Sotiriou, Christos; Scherer, Stefan J; Ignatiadis, Michail; Badve, Sunil; Pierce, Robert H; Viale, Giuseppe; Sirtaine, Nicolas; Penault-Llorca, Frederique; Sugie, Tomohagu; Fineberg, Susan; Paik, Soonmyung; Srinivasan, Ashok; Richardson, Andrea; Wang, Yihong; Chmielik, Ewa; Brock, Jane; Johnson, Douglas B; Balko, Justin; Wienert, Stephan; Bossuyt, Veerle; Michiels, Stefan; Ternes, Nils; Burchardi, Nicole; Luen, Stephen J; Savas, Peter; Klauschen, Frederick; Watson, Peter H; Nelson, Brad H; Criscitiello, Carmen; O'Toole, Sandra; Larsimont, Denis; de Wind, Roland; Curigliano, Giuseppe; André, Fabrice; Lacroix-Triki, Magali; van de Vijver, Mark; Rojo, Federico; Floris, Giuseppe; Bedri, Shahinaz; Sparano, Joseph; Rimm, David; Nielsen, Torsten; Kos, Zuzana; Hewitt, Stephen; Singh, Baljit; Farshid, Gelareh; Loibl, Sibylle; Allison, Kimberly H; Tung, Nadine; Adams, Sylvia; Willard-Gallo, Karen; Horlings, Hugo M; Gandhi, Leena; Moreira, Andre; Hirsch, Fred; Dieci, Maria V; Urbanowicz, Maria; Brcic, Iva; Korski, Konstanty; Gaire, Fabien; Koeppen, Hartmut; Lo, Amy; Giltnane, Jennifer; Rebelatto, Marlon C; Steele, Keith E; Zha, Jiping; Emancipator, Kenneth; Juco, Jonathan W; Denkert, Carsten; Reis-Filho, Jorge; Loi, Sherene; Fox, Stephen B; John, Thomas |
| 16 | 26-Sep-2017 | Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. | Chüeh, Anderly C; Liew, Mun-Sem; Russell, Prudence A; Walkiewicz, Marzena; Jayachandran, Aparna; Starmans, Maud H W; Boutros, Paul C; Wright, Gavin; Barnett, Stephen A ; Mariadason, John M ; John, Thomas |
| 17 | 2-Sep-2017 | Standard of care in immunotherapy trials: Challenges and considerations. | Rivalland, Gareth; Scott, Andrew M ; John, Thomas |
| 18 | Sep-2017 | De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer. | Thai, Alesha; Chia, Puey L; Russell, Prudence A; Do, Hongdo; Dobrovic, Alexander ; Mitchell, Paul L R ; John, Thomas |
| 19 | Aug-2017 | Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer | John, Thomas ; Bowden, Jeffrey J; Clarke, Stephen; Fox, Stephen B; Garrett, Kerryn; Horwood, Keith; Karapetis, Christos S |
| 20 | Aug-2017 | Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer. | Tamjid, Babak ; Phan, Phuong L; John, Thomas ; Mitchell, Paul L R ; Gan, Hui K |
Loading...
2
0
20
0
false
0000-0003-3399-5342